Prognostic Analysis of Esophageal Cancer with Complete Pathological Response After Neoadjuvant Therapy

NCT06889402 · clinicaltrials.gov ↗

NOT_YET_RECRUITING

Status

600

Enrollment

OTHER

Sponsor class

Conditions

Esophageal Cancer

Interventions

PROCEDURE: Neoadjuvant therapy with PD-L1 inhibitor

Sponsor

Cancer Institute and Hospital, Chinese Academy of Medical Sciences